Monitor for effectiveness of the registration statement and any subsequent warrant exercises, which would provide capital but also cause dilution. The company's ability to raise additional funds is critical for its regulatory strategy and going concern status.
Executive Summary
Cellectar Biosciences filed Amendment No. 1 to its S-1 registration statement to register up to 51,998,413 shares of common stock for resale by selling stockholders, including shares issued in a May 2026 private placement and shares issuable upon exercise of warrants. The company will not receive proceeds from the resale but could receive up to $108.2 million if all warrants are exercised for cash. The filing highlights the company's pre-revenue status, going concern risk, and need for additional capital to fund regulatory strategy for its lead candidate iopofosine I 131.
Key Facts
- Registers up to 51,998,413 shares for resale by selling stockholders from May 2026 private placement and related warrants.
- Company will not receive proceeds from share resales; could receive up to $108.2 million if all warrants exercised for cash.
- As of December 31, 2025, cash balance was approximately $13.2 million, adequate to fund operations into Q2 2027.
- Company has a going concern risk and requires additional capital to execute regulatory strategy for iopofosine I 131.
- Lead candidate iopofosine I 131 has Breakthrough Therapy Designation and Fast Track designation from FDA for Waldenstrom macroglobulinemia.
- Company restated financial statements for years ended December 31, 2022 and 2023 and identified material weaknesses in internal controls.
- On May 18, 2026, last reported sale price of common stock was $3.14 per share.
- Nantahala Capital Management designated Andrew Gu to the Board of Directors.
- Concurrently with the private placement, company issued 1,618,053 shares in a registered direct offering.
Financial Impact
Up to $108.2 million potential gross proceeds from warrant exercises; $30.7 million gross proceeds from private placement already received.
Risk Factors
- Going concern risk: company needs additional capital to fund operations and regulatory strategy.
- Regulatory risk: iopofosine I 131 may not receive FDA or EMA approval.
- Dilution risk: up to 51.9 million shares registered for resale, representing massive potential dilution.
- Restatement and material weaknesses in internal controls increase regulatory and litigation risk.
- Pre-revenue status with no approved products and history of operating losses.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001104659-26-067933 |
| Document: tm2614975d2_exfilingfee.htm | 0001104659-26-067933 |
| Document: tm2614975d2_ex5-1.htm | 0001104659-26-067933 |
| Document: tm2614975d2_ex23-2.htm | 0001104659-26-067933 |
| Document: 0001104659-26-067933-index-headers.html | 0001104659-26-067933 |
| Document: 0001104659-26-067933-index.html | 0001104659-26-067933 |
| Document: 0001104659-26-067933.txt | 0001104659-26-067933 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $1.19 | awaiting T+60 | — | $1.22 (+2.52%) |
Aug 13, 2026 10w ago | 8-K | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Aug 13, 2026 10w ago | Press Release | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Jun 1, 2026 21w ago | Press Release | $2.97 $2.54 | ▼ −14.48% | ▼ −15.71% | $1.22 (−58.92%) |
May 29, 2026 21w ago | S-1/A | $3.14 $2.52 | ▲ +19.75% | ▲ +20.93% | $1.22 (+61.15%) |
May 28, 2026 21w ago | DEFA14A | $3.14 $2.52 | ▼ −19.75% | ▼ −20.93% | $1.22 (−61.15%) |
May 19, 2026 22w ago | S-1 | $3.17 $2.60 | ▲ +17.98% | ▲ +22.98% | $1.22 (+61.51%) |
May 14, 2026 23w ago | 8-K | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 14, 2026 23w ago | Press Release | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 11, 2026 24w ago | Press Release | $3.06 $2.52 | ▼ −17.65% | ▼ −22.04% | $1.22 (−60.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers